Mounjaro
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
What is Mounjaro?
Tirzepatide sold as a weekly injection for type 2 diabetes, approved 2022 for adults and now also for children 10 and older.
Since August 2026 it is also approved to lower the chance of a heart attack, stroke or cardiovascular death for diabetic adults whose risk of such events is high. It is the same molecule as Zepbound with a different label, and it carries the same four-week backup-contraception warning for anyone on oral hormonal contraceptives.
Related reading: GLP-1s and Hormonal Birth Control: Which Labels Carry the Warning
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Mounjaro comes up on this site
On GLP Watchdog, Mounjaro comes up in 82 research articles, 39 seller reviews, 11 FDA warning letters and 4 tools. Browse the FDA warning letters.
Research that discusses it
- Blurred Vision on Ozempic or Mounjaro: Causes, How Long It Lasts, When It's Urgent
- Mounjaro Alternatives: What Costs Less and What You Give Up
- Which Drugs Are GLP-1s? Mounjaro, Trulicity, Phentermine and 25 More, Checked
- Can Ozempic or Mounjaro Cause Liver Damage? Liver Enzymes Evidence Review
- Coffee on Ozempic, Wegovy or Mounjaro: What the Labels and Studies Say
- Mounjaro Heart Protection: What SURPASS-CVOT Found and What FDA Approved
- All 82 articles are on the research page
Drug pages
Tools that use it
Seller reviews that mention it
Other terms under Drugs and brands
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers